University of Ioannina
Ο ρόλος της retinol binding protein 4 (RBP4) σε άτομα με αυξημένο σωματικό βάρος και υπερτριγλυκεριδαιμία
Abstract
dc:descriptionObjective: The objective of this study was the investigation of the relationship between retinol binding protein 4 (RBP4) and atherogenic apolipoprotein B (ApoB)-containing lipoproteins, as a possible mechanism underlying the association between RBP4 and cardiovascular disease. Moreover, this study aimed to investigate the relationship between high density lipoprotein (HDL) and adiponectin.Design: Forty six obese or overweight subjects [body mass index (BMI) ≥ 27 Kg/m2] with hypertriglyceridemia underwent one of the following interventions for 3 months: 1) Lowcalorie low-fat diet (n= 20), 2) Low-calorie low-fat diet plus fenofibrate (n= 18), 3) Low-calorie low-fat diet plus rimonabant (n= 8). At baseline, at one month and at 3 months of treatment the following measurements were performed: anthropometric measurements, serum glucose, serum insulin, lipidemic profile, analysis of low density lipoprotein-cholesterol (LDL-C) subfractions, plasma concentration of RBP4, plasma total adiponectin levels and plasma high molecular weight (HMW) adiponectin levels.Results for RBP4: Circulating RBP4 decreased over 3 months of diet. RBP4 levels at one month of diet were positively correlated with the percentage change of Apolipoprotein B (ApoB) and small dense LDL (sdLDL) over one month of diet. The percentage change of circulating RBP4 over 3 months of diet was positively correlated with the percentage change of serum triglycerides, very low density lipoprotein-cholesterol (VLDL-C), LDLC, ApoB and sdLDL-C. In multivariate analysis, the percentage change of circulating RBP4 over 3 months of diet was the most powerful independent predictor of the percentage changes of ApoB and sdLDL-C. Fenofibrate treatment induced an increase in circulating RBP4 over the first month, because of the fenofibrate-induced reduction in renal clearance of RBP4, and a subsequent reduction of plasma RBP4 levels over the later 2 months, that was attributed to the metabolic action of fenofibrate. Rimonabant treatment reduced circulating RBP4.Results for adiponectin: Circulating total adiponectin did not change significantly during diet. In the subgroup of patients whose HDL-C decreased over the first month of diet, a decrease in circulating total adiponectin was found. In the subgroup of patients whose HDL-C increased over the later 2 months of diet, an increase in circulating total adiponectin over the 2 months was found. The percentage change of HDL-C over the first month of diet was positively correlated with the percentage change of circulating total adiponectin. The percentage change of HDL-C over 3 months of diet was positively correlated with the percentage changes of circulating total adiponectin and HMW adiponectin. The change in circulating total adiponectin over the first month of diet was positively correlated with HDL-C at one month. The change in HMW adiponectin over 3 months of diet was positively correlated with HDL-C at 3 months. The percentage change of circulating HMW adiponectin over the first month of fenofibrate treatment was positively correlated with the percentage change of HDL-C.Conclusions for RBP4: RBP4 is possibly linked with the metabolic pathway, that is responsible for the changes of ApoB-containing lipoproteins. This mechanism could interprete the relationship between RBP4 and cardiovascular disease.Conclusions for adiponectin: HDL is positively correlated with the changes in circulating adiponectin, during dietary and fenofibrate treatment.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christou, Georgios
- Χρήστου, Γεώργιος
Subjects
dc:subject × 20- Συνδετική πρωτεΐνη 4 της ρετινόλης
- Παχυσαρκία
- Υπερτριγλυκεριδαιμία
- Δίαιτα
- Φαινοφιμπράτη
- Ριμοναμπάντη
- Απολιποπρωτεΐνη Β
- Υψηλής πυκνότητας λιποπρωτεΐνες
- Retinol binding protein 4
- Obesity
- Hypertriglyceridemia
- Diet
- Fenofibrate
- Rimonabant
- Apolipoprotein B
- High density lipoprotein (HDL)
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39914